In a randomized phase Ib study, patients receiving the combination of GVAX and anti-CTLA-4 mAb (ipilimumab) had improved overall survival (median 5.7 months) compared to patients receiving ipilimumab alone (3.6 months) Patients with prolonged survival showed a higher number of tumor-infiltrating CD8+ T cells in the TME, indicating an improved antitumor immune response. The gene discussed is CTLA4; the disease is neoplasm.